Shares of United Therapeutics Corporation (UTHR) gained over 12% on Monday morning after the company reported strong Phase 3 clinical results for its lung disease therapy.
The stock is currently trading at $585.59, up $62.76 or 12.05%, on the Nasdaq. It opened at $604.64 after closing the previous session at $522.83. The stock has traded between $522.83 and $604.64 in the latest session.
United Therapeutics announced that its TETON-1 pivotal study met its primary endpoint, with Tyvaso (treprostinil) demonstrating superiority over placebo in improving lung function in patients with idiopathic pulmonary fibrosis (IPF).
The treatment showed a 130.1 mL improvement in forced vital capacity (FVC) and significantly reduced the risk of clinical worsening, with benefits observed across all patient subgroups.
The company said it plans to submit a supplemental NDA to the FDA by the end of summer 2026, seeking approval to expand Tyvaso's label to include IPF, a move that could significantly broaden its commercial opportunity.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.